Coya Therapeutics Announces Completion Of Enrollment In A Well-Controlled Phase 2 Study Of Low Dose Interleukin-2 In Patients With Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Coya Therapeutics has completed enrollment for a Phase 2 study of low dose Interleukin-2 (LD IL-2) in patients with Alzheimer's Disease. The study, funded by the Gates Foundation and Alzheimer's Association, will evaluate the safety, tolerability, and preliminary efficacy of LD IL-2 in 38 patients over 30 weeks. Previous data showed significant improvement in cognitive function with LD IL-2 treatment. Coya's proprietary LD IL-2 (COYA 301) is being developed as a treatment for Alzheimer's and in combination with CTLA4 Ig (COYA 302) for Amyotrophic Lateral Sclerosis (ALS).
October 09, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coya Therapeutics has completed enrollment for a Phase 2 study of its proprietary LD IL-2 (COYA 301) in Alzheimer's patients. The study's results could potentially impact the company's stock price.
The completion of enrollment for the Phase 2 study is a significant milestone for Coya Therapeutics. If the study's results are positive, it could lead to regulatory approval and potential commercialization of the drug, which would likely have a positive impact on the company's stock price. However, the results are not yet known, hence the confidence score is not at the maximum.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100